Status:
COMPLETED
AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours
Lead Sponsor:
AstraZeneca
Conditions:
Solid Tumor
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
This is a dose escalation study to assess the safety and tolerability of AZD0530 in patients with advanced solid malignancies.
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed advanced carcinoma / solid tumour of known primary site, which is refractory to standard therapies or for which no standard therapy exists
- World Health Organisation (WHO) performance status 0 to 2
- Life expectancy of at least 12 weeks
Exclusion
- Inadequate bone marrow reserve
- Inadequate liver function, renal function or low hemoglobin
- Unresolved toxicity from anti-cancer therapy
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00704366
Start Date
June 1 2008
End Date
May 1 2011
Last Update
May 16 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Takatsuk, Osaka, Japan
2
Research Site
Sunto-gun, Shizuoka, Japan